Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"Palette Life Sciences","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Palette Life Sciences Secures Loan Facility for Up to $40 Million with Silicon Valley Bank","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Palette Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palette Life Sciences Receives Favorable Post Approval Study Results for Solesta","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Palette Life Sciences

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The prospective, single-arm study followed a population of 283 patients and determined that Solesta provided clinically significant, sustained improvement in symptoms and quality of life, without the occurrence of any serious adverse events.

            Lead Product(s): Hyaluronic Acid,Dextranomer

            Therapeutic Area: Gastroenterology Product Name: Solesta

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 29, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The non-dilutive capital provides financial support for commercial and product development including Barrigel, is made from NASHA. Barrigel is an injectable biodegradable material that separates prostate from rectum to protect it during radiation therapy for prostate cancer.

            Lead Product(s): Hyaluronic Acid

            Therapeutic Area: Oncology Product Name: Barrigel

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Silicon Valley Bank

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing October 28, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY